Your browser doesn't support javascript.
loading
Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG).
Duffaud, F; Meeus, P; Bachet, J B; Cassier, P; Huynh, T K; Boucher, E; Bouché, O; Moutardier, V; le Cesne, A; Landi, B; Marchal, F; Bay, J O; Bertucci, F; Spano, J P; Stoeckle, E; Collard, O; Chaigneau, L; Isambert, N; Lebrun-Ly, V; Mancini, J; Blay, J Y; Bonvalot, S.
Afiliação
  • Duffaud F; Service d'Oncologie Médicale, CHU Timone, AP-HM, Marseille, and Aix-Marseille Université (AMU), Marseille, France. Electronic address: fduffaud@mail.ap-hm.fr.
  • Meeus P; Service de Chirurgie, Centre Léon Bérard, Lyon, France.
  • Bachet JB; Service d'Hépato-gastroentérologie, CHU Pitié Salpétrière, Paris, France.
  • Cassier P; Service d'Oncologie Médicale, Centre Léon Bérard, Lyon, France.
  • Huynh TK; Service d'Oncologie Médicale, CHU Timone, AP-HM, Marseille, and Aix-Marseille Université (AMU), Marseille, France.
  • Boucher E; Service d'Oncologie médicale, Centre Eugène Marquis, Rennes, France.
  • Bouché O; Service d'Oncologie digestive, CHU de Reims, France.
  • Moutardier V; Service de Chirurgie digestive, CHU Nord, Marseille, France.
  • le Cesne A; Service d'Oncologie médicale, Institut Gustave Roussy, Villejuif, France.
  • Landi B; Service de Gastro-entérologie et Oncologie digestive, Hôpital Européen Georges Pompidou, Paris, France.
  • Marchal F; Département de Chirurgie, Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France.
  • Bay JO; Service d'oncologie médicale, CHU Clermont Ferrand, France.
  • Bertucci F; Service d'Oncologie médicale, Institut Paoli Calmettes, Marseille, France.
  • Spano JP; Service d'Oncologie médicale, CHU Pitié Salpétrière, Paris, France.
  • Stoeckle E; Service d'Oncologie médicale, Institut Bergonié, Bordeaux, France.
  • Collard O; Service d'Oncologie Médicale, CLCC, Institut de Cancérologie Lucien Neuwirth, Saint-Etienne, France.
  • Chaigneau L; Service d'oncologie médicale, CHU de Besançon, France.
  • Isambert N; Oncologie médicale, Centre G Leclerc, Dijon, France.
  • Lebrun-Ly V; Service d'Oncologie médicale, CHU Dijon, France.
  • Mancini J; Service de Santé Publique et d'Information Médicale, Unité de Biostatistiques, CHU Timone, Marseille, and Aix-Marseille Université (AMU), France.
  • Blay JY; Service d'Oncologie Médicale, Centre Léon Bérard, Lyon, France.
  • Bonvalot S; Service de Chirurgie, Institut G Roussy, Villejuif, France.
Eur J Surg Oncol ; 40(10): 1369-75, 2014 Oct.
Article em En | MEDLINE | ID: mdl-24994075
BACKGROUND: Duodenal GISTs represent 3-5% of all GISTs with limited understanding of patient outcomes. We conducted a retrospective analysis of primary localized duodenal GISTs. METHODS: Patients were identified via a survey from 16 FSG centers (n = 105), and a group of 9 patients enrolled in the BFR14 trial. Data were collected from the original database and patient files, in agreement with French legislation. RESULTS: 114 patients were included, with a median age of 57. Tumors originated mainly in D2 (33%), or D3 (24%), with a median size of 5 cm. 109 patients had resection of the primary tumor; with a Local Resection (LR, n = 82), a pancreaticoduodenectomy (PD, n = 23), and data were missing for 4 patients. Resections were R0 (n = 87, 79%), R1 (n = 8, 7%), R2 (n = 6). Tumor characteristics were: KIT+ (n = 104), CD34+ (n = 58). Miettinen risk was low (n = 43), and high (n = 52). Imatinib was administered preoperatively (n = 11) and post-operatively (n = 20). With a median follow-up of 36 months (2-250), 98 patients are alive, and 33 relapsed. The 5-year OS and EFS rates are 86.5% and 54.5%. EFS was similar for patients in the LR and the PD groups (P > 0.05). In multivariate analysis, ECOG PS, and CD34 expression are independent prognostic factors on OS. Miettinen risk and spindle cell type are independent predictive factors for relapse. CONCLUSIONS: Patients with resected duodenal GIST have a reasonably favorable prognosis. This study favors a preservation of pancreas when there are no anatomical constraints. LR exhibit similar survival and smaller morbidity then PD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pancreaticoduodenectomia / Tumores do Estroma Gastrointestinal / Neoplasias Duodenais / Duodeno / Tratamentos com Preservação do Órgão / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pancreaticoduodenectomia / Tumores do Estroma Gastrointestinal / Neoplasias Duodenais / Duodeno / Tratamentos com Preservação do Órgão / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2014 Tipo de documento: Article